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Abstract
Conserved embryonic signaling pathways such as Hedgehog (Hh), Wingless and Notch have been implicated in the
pathogenesis of several malignancies. Recent data suggests that Hh signaling plays a role in normal B-cell development, and
we hypothesized that Hh signaling may be important in precursor B-cell acute lymphocytic leukemia (B-ALL). We found that
the expression of Hh pathway components was common in human B-ALL cell lines and clinical samples. Moreover, pathway
activity could be modulated by Hh ligand or several pathway inhibitors including cyclopamine and the novel SMOOTHENED
(SMO) inhibitor IPI-926. The inhibition of pathway activity primarily impacted highly clonogenic B-ALL cells expressing
aldehyde dehydrogenase (ALDH) by limiting their self-renewal potential both in vitro and in vivo. These data demonstrate
that Hh pathway activation is common in B-ALL and represents a novel therapeutic target regulating self-renewal and
persistence of the malignant clone.
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Introduction
During embryonic development, conserved signaling pathways
such as Hedgehog (Hh), Wingless (Wnt) and Notch precisely regulate
morphogenesisbydictatingcellfatedecisionssuchasself-renewaland
differentiation [1]. These pathways are subsequently silenced in most
adult tissues but frequently reactivated in a wide range of human
malignancies. It has been hypothesized that malignant transforma-
tion recapitulates many developmental processes, and signaling
pathways required for the normal development of a specific tissue or
organ may be aberrantly activated in the corresponding malignancy.
For example, the Notch pathway is required for normal T cell
development, and deregulated Notch signaling is a common feature
of T-cell acute lymphocytic leukemia (ALL) [2]. Preliminary reports
also suggest that Hedgehog signaling promotes the growth of T-ALL
[3,4]. The role of developmental signaling pathways in the
pathogenesis and self-renewal of B cell ALL (B-ALL) is not clear,
but recent data suggest that the Hh signaling pathway is involved in
the development of B cell precursors from primitive hematopoietic
stem cells, as well as self-renewal and cell survival in human B cell
malignancies [5–8].
In mammalian cells, key components of the Hh signaling
pathway have been identified. The three Hh ligands (Sonic, Indian
and Desert) activate pathway signaling by binding to the cell
surface receptor Patched (PTCH). In the unbound state, PTCH
exerts an inhibitory effect on Smoothened (SMO). However, when
PTCH is bound to ligand, this inhibition is released and eventually
modulates the activities of the three GLI transcription factors
(GLI1-3) at target promoters. Evidence that the Hh pathway is
involved in human cancers is exemplified by Gorlin syndrome
arising from autosomal dominant mutations in PTCH1 that
dramatically increase the risk of advanced basal cell carcinoma
(BCC), medulloblastoma and rhabdomyosarcoma [9]. Spontane-
ous mutations in PTCH and SMO that confer aberrant pathway
activity are also commonly found in spontaneous cases of BCC
and medulloblastoma. Increased Hh signaling has been described
in a wide range of other human cancers, including chronic
myeloid leukemia (CML), multiple myeloma (MM), pancreatic
cancer, glioblastoma, prostate cancer, breast cancer and small cell
lung cancer [6,8,10–14]. The vast majority of these tumors lack
mutational activation of Hh pathway components, and increased
Hh signaling may be due to over-expression of activating ligands
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result in reduced tumor cell proliferation or survival. Evidence that
the Hh signaling pathway plays a role in several B cell
malignancies including MM and non-Hodgkin lymphoma
(NHL) as well as normal early B-cell development suggests that
it may be involved in precursor B-ALL [6,8,17]. Moreover, in
several human hematologic malignancies, the Hh signaling
pathway has been found to regulate self-renewal required for
long-term maintenance of the malignant clone [6,18,19]. We
examined Hh signaling pathway activity in B-ALL and found that
Hh signaling regulates the self-renewal of highly clonogenic tumor
cells both in vitro and in vivo. These results suggest that the
inhibition of Hh signaling may improve long-term outcomes in B-
ALL by targeting the clonogenic cells responsible for disease
relapse.
Materials and Methods
Ethics Statement
Primary clinical specimens were obtained from patients with
newly diagnosed or relapsed B-ALL. Normal bone marrow CD34
+
CD19
+ progenitors from normal bone marrow donors were used as
controls in real-time PCR experiments. All patients granted written
informed consent as approved by the UCLA Institutional Review
Board (Medical Institutional Review Board 2).
Cells and cell culture
Human precursor B-ALL cell lines were obtained from the
American Type Tissue Collection (REH, RS4;11) and the DMSZ
German Collection of Microorganisms and Cell Culture (Nalm 6,
SEM-K2, TOM-1). The HB-1119 cell line was a gift of M. Cleary
(Stanford University). Cells were maintained in Advanced RPMI
(Invitrogen) containing 1% fetal bovine serum (FBS) and L-
glutamine. Primary clinical specimens were obtained from patients
with newly diagnosed or relapsed B-ALL. Normal bone marrow
CD34
+ CD19
+ progenitors from normal bone marrow donors
were used as controls in real-time PCR experiments. All patients
granted informed consent as approved by the UCLA Institutional
Review Board. Mononuclear cells were isolated from freshly
harvested bone marrow aspirates or peripheral blood by density
centrifugation (density ,1.078, Ficoll Paque, Pharmacia) followed
by two washes with RPMI.
Expression of Hh pathway components
The expression of Hh pathway components DHH, IHH, SHH,
HHIP, GAS, PTCH1, PTCH2, SMO, GLI1, GLI2, GLI3 in precursor
B-ALL cell lines was detected by reverse-transcriptase PCR.
Human fetal brain (HFB) was used as a positive control for Hh
pathway expression, and a ˆ-actin was used as a control gene for
experiments with cell lines and HFB with and without reverse
transcriptase. Levels of PTCH1, SMO and GLI1 were measured in
cell lines and primary clinical specimens by real-time quantitative
PCR using the Step 1 Plus thermal cycler and Fast Taqman
reagent (Applied Biosystems). Clinical specimens which expressed
all three genes PTCH1, SMO and GLI1 were considered to positive
for expression of Hh pathway components. Normal bone marrow
CD34
+ CD19
+ progenitors from normal bone marrow donors
were used as controls in real-time PCR experiments. Quantitative
calculations were performed using the A ¨A ¨
ct method. Primer
sequences are listed in Supplemental Table S1.
Hh pathway agonists and inhibitors
Recombinant Sonic Hedgehog (ShhNP) was a gift of P. Beachy
(Stanford University). The monoclonal antibody 5E1 was obtained
from the Iowa Hybridoma Bank [20]. The naturally occurring
SMO inhibitor cyclopamine and the semi-synthetic cyclopamine
derivative IPI-926 were provided by Infinity Pharmaceuticals
[21].
Transient transfection studies
REH and RS4;11 precursor B ALL cells were co-transfected
with a Gli-responsive firefly luciferase vector containing 8 tandem
copies of a consensus Gli binding site immediately upstream of the
chicken lens crystallin promoter (pGL3-86-Gli-luciferase) and
constitutive Renilla luciferase expression vectors (pRL-CMV;
Promega) using the Amaxa Nucleofector Apparatus (Lonza)
[22]. Transfected cells were then treated with Hh pathway
modulators for 48 hours. Treated cells were then harvested and
assayed for firefly and Renilla luciferase activities using the dual
luciferase reporter assay (Promega).
Clonogenic assays
REH and RS4;11 cells were seeded at 1610
5 cells/ml and
treated with ShhNP, 5E1, cyclopamine (5 mM) or IPI-926 (1 mM)
for 72 hours. Following 72 hours of treatment, cells were washed
twice with media to remove drugs then 500 cells were plated in
quadruplicate in 1 ml of 1.2% methylcellulose, 30% FBS, 1%
bovine serum albumin (BSA), 0.1 mM 2-mercaptoethanol, and
2 mM L-glutamine. Samples were plated in quadruplicate onto
35 mm
2 tissue culture dishes and incubated in a humidified
atmosphere at 37uC and 5% CO2. Colonies consisting of .40 cells
were counted using an inverted microscope at 10–14 days, then
harvested and replated in methylcellulose.
20 Results represent
colony formation during each round of replating relative to vehicle
control cells.
Examination of ALDH activity by flow cytometry
REH and RS4;11 cells were evaluated for aldehyde dehydro-
genase (ALDH) activity using the Aldefluor reagent (Stem Cell
Technologies) according to the manufacturer’s instructions
followed by flow cytometry with a FACSCalibur flow cytometer.
Viable cells were distinguished by the lack of staining with
propidium iodide (1 mg/ml) and considered positive for ALDH
based on a control staining reaction using the enzyme inhibitor
diethylaminobenzaldehyde (DEAB). Cell sorting was performed
using a FACSAria flow cytometer, and viable cells with the lowest
5% Aldefluor staining were considered ALDH negative.
NOD/SCID mice
All animal experiments were conducted in accordance with
protocols approved by the Johns Hopkins Institutional Animal
Care and Use Committee. For in vivo treatment studies, NOD/
Scid mice were injected with 10
4 REH cells by tail vein 18–
24 hours after irradiation (300 cGy). The day after cell injection,
mice were treated twice a week for 3 weeks with the SMO
inhibitor IPI-926 (40 mg/kg IP), then followed until the
development of symptoms (weight loss or paralysis) and sacrificed
for analysis. Harvested bone marrow and spleen cells were stained
with antibodies directed against human CD19 and CD45 (BD
Biosciences) followed by flow cytometry. Animals were considered
positive for engraftment if human CD45
+CD19
+ cells were .1%
of cells. For secondary transplants, bone marrow cells (10
5 total
human CD19
+ cells) were injected by tail vein into irradiated
NOD/Scid mice as above. No treatment was administered to
secondary recipients. For in vitro treatment studies, REH cells were
initially treated in culture with IPI-926 (1 mM) for 14 days. Cells
were harvested, washed twice with media then injected by tail vein
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detection of symptoms and analyzed as above.
Statistical analysis
Data are expressed as the mean 6 standard error of the mean
(SEM). Comparisons between treatments were performed using a
two-tailed, paired Student’s t test. Mouse studies were analyzed
using a Kaplan-Meier analysis and the log-rank test. For all
analyses, P,0.05 was considered statistically significant.
Results
Human precursor B-ALL cell lines and clinical samples
express Hedgehog pathway components
B-ALL is a heterogeneous disorder with several cytogenetic
variants that correlate with distinct clinical outcomes. We
examined a panel of human precursor B-ALL cell lines reflecting
this heterogeneity for expression of Hh pathway components by
RT-PCR and found that each expressed several of the Hh
pathway components (Figure 1). All cell lines in our panel
expressed GAS, PTCH1, PTCH2, SMO and GLI1 and a majority of
cell lines expressed Hh ligands, HHIP, GLI2 and GLI3. Moreover,
expression of the Hh target genes PTCH1 and GLI1 suggest that
Hh signaling was active in these lines. We extended these studies
and quantified the expression of PTCH1, SMO and GLI1 by each
of these cell lines as well as primary B-ALL clinical specimens
using real-time PCR (Table 1). Compared to previous studies in
MM in which only a fraction of primary tumors expressed Hh
pathway components [6,23] a high proportion of the primary B-
ALL specimens (39/41, 95%) expressed all three genes PTCH1,
SMO and GLI1 (noted as ‘‘Hh pathway expression’’ in Table 1).
Moreover, expression was detected in specimens that encompassed
the most curable (TEL-AML1), most common (normal cytoge-
Figure 1. Expression of Hh pathway components is common in
precursor B-ALL cell lines. Qualitative RT-PCR analysis of Hh
pathway gene expression in precursor B-ALL cell lines. HFB, human
fetal brain, used as positive control for all experiments. For each cell
line, positive and negative control reactions were run with B-actin
primers with (to demonstrate equal amounts of cDNA template across
each cell line) and without (to rule out contamination with genomic
DNA) reverse transcriptase. B-ACTIN- denotes PCR results from mock
cDNA synthesis reactions lacking RT. Precursor B-ALL cell lines: HB 1119
(t11;19), Nalm6 (t2;6), REH (t12;21), RS4;11 (MLL gene rearrangement);
SEM-K2 (MLL gene rearrangement), TOM-1 (Ph
+). Electrophoresis was
performed with each gene separately across the panel of cell lines. The
separate gels are shown together for the purpose of clarity across cell
lines in the figure.
doi:10.1371/journal.pone.0015262.g001
Table 1. Hh pathway components are commonly expressed
in primary clinical specimens across cytogenetic and
prognostic subgroups of precursor B-ALL.
ALL Cytogenetic Subtype Hh pathway expression
TEL-AML1 translocation 9/10
Normal karyotype 17/17
Hyperdiploid karyotype 5/5
Philadelphia chromosome 2/2
Other cytogenetic findings 6/7
TOTAL 39/41
Expression of Hh pathway components PTCH1, SMO and GLI-1 was measured by
quantitative RT-PCR in a panel of 41 clinical specimens from patients with newly
diagnosed or relapsed ALL from various cytogenetic subtypes. Hh pathway
expression was defined as those specimens with expression of all three genes
(PTCH1, SMO and GLI1) and was seen in the majority of clinical specimens (39/
41). Expression of Hh pathway components was seen across all cytogenetic
subtypes, including those with good and poor prognosis.
doi:10.1371/journal.pone.0015262.t001
Figure 2. Hh pathway is active and inhibited by the SMO-
inhibitors cyclopamine and IPI-926. Precursor B-ALL cell lines REH
and RS4;11 were transiently transfected with a Gli-responsive luciferase
reporter or pGL3-basic, a plasmid lacking GLI binding site, as a negative
control. Relative luciferase levels were measured following 48 hours of
treatment with vehicle control, purified, dual lipid-modified Shh ligand
(Shh-NP), SHh antibody 5E1 (10 mg/ml), cyclopamine (5 mM) or IPI-926
(1 mM). Hh pathway stimulation with SHh (p,0.005) and inhibition with
5E1 (p,0.0001), cyclopamine (p,0.0005) and IPI-926 (p,0.0002) was
statistically significant in both the REH and RS4;11 cell lines.
doi:10.1371/journal.pone.0015262.g002
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although the quantitative expression of Hh pathway components
did not correlate with any specific B-ALL subtype (data not
shown).
Hedgehog signaling is active in precursor B-ALL and
inhibited by cyclopamine and IPI-926
In order to determine whether the Hh signaling pathway is
active in B-ALL, we carried out transient transfection experiments
with a GLI-responsive luciferase reporter and studied REH and
RS4;11 cells since they are representative of good and poor risk
ALL, respectively. Both cell lines demonstrated significantly higher
baseline reporter activity compared to a control plasmid that
lacked GLI binding sites (Figure 2, p,0.0004). Next, we examined
the effects of HH pathway modulation at the level of the Hh ligand
by stimulation with the recombinant Hh ligand SHh-NP and Hh
pathway inhibition by the monoclonal antibody against the Hh
ligand, 5E1. Cells were treated for 48 hours with SHh-NP or 5E1.
Reporter activity was enhanced by exogenous SHh ligand
(p,0.005) and inhibited by the ligand-neutralizing monoclonal
antibody 5E1 (p,0.0001), suggesting that Hh signaling was ligand
dependent and not likely due to activating mutations within
pathway components. We also studied the inhibitory activity of
two SMO inhibitors, cyclopamine and IPI-926 [21]. Following
48 hours of treatment, both these inhibitors significantly inhibited
luciferase reporter activity (cyclopamine, p,0.0005, IPI-926,
p,0.0002), suggesting that the activity of the Hh signaling
pathway could be externally modulated in B-ALL.
Hh pathway inhibition limits clonogenic growth of
precursor B-ALL cell lines
We previously demonstrated that aberrant Hh signaling plays a
role in the self-renewal of MM and glioblastoma [6,11], and
similar findings have been reported in CML [18,19]. In these
studies, self-renewal was attributed to distinct populations of tumor
cells termed tumor initiating cells or cancer stem cells (CSC). CSC
have been reported in B-ALL, but a universal phenotype has not
been described and is likely to vary according to the specific B-
ALL subtype.
16–21 Tumorigenic cells have been identified using
specific surface antigen expression in most diseases, but stem cells
may be isolated from normal tissues based on processes conferring
drug resistance such as ABCG2 and aldehyde dehydrogenase
(ALDH) [24–26]. Relative ALDH activity can identify highly
clonogenic cell populations in a number of B cell malignancies,
such as MM and Hodgkin lymphoma [27,28], and we found that
the REH and RS4;11 cell lines contained small populations (,1%)
of ALDH
+ cells (Figure 3A). We isolated ALDH
+ and ALDH
neg
cells from each line by FACS and found that ALDH
+ cells formed
5–7 fold more colonies than ALDH
neg cells in methylcellulose
(Figure 3B, p=0.05 for REH, p,0.01 for RS4;11). Moreover, this
difference significantly increased during serial replating (Figure 3C,
p,0.002 for REH, p,0.001for RS4;11), a surrogate for self-
renewal potential. Therefore, ALDH expression may be associated
with increased self-renewal potential in B-ALL.
In order to determine whether Hh pathway activity plays a role
in regulating the self-renewal of precursor B-ALL cells, REH and
RS4;11 cells were treated with cyclopamine or IPI-926 and then
Figure 3. ALDH
+ cells are enriched for self-renewal potential
and targeted by IPI-926. (A)ALDH
+ and ALDH
neg cells were isolated
from the REH cell line by FACS using the Aldefluor reagent and DEAB
control. The gated area represents the ALDH
+ cells, measuring 1.18% of
total REH population. (B) ALDH
+ and ALDH
neg cells from REH and RS4;11
were plated in methylcellulose to evaluate clonogenic growth. Colony
formation was measured at 10–14 days. There was a 5-fold difference in
colony number following initial plating for REH (p=0.05) and RS4;11
(p,0.01). (C) A representative plate from initial plating was washed
with media and cells resuspended prior to replating in methylcellulose
for an additional 10-14 days. Secondary plating of ALDH
+ and ALDH
neg
cells demonstrated an 8-fold difference in colony-formation between
the ALDH
+ and ALDH
neg cell fractions for REH (p,0.002) and RS4;11
(p,0.001). (D)Unfractionated REH and RS4;11 cells were treated with
cyclopamine (5 mM), IPI-926 (1 mM) or vehicle control for 10 days and
the percentage of ALDH
+ and ALDH
neg cells was measured using the
Aldefluor staining kit and FACS. The reduction in ALDH
neg cells
following treatment with cyclopamine and IPI-926 was statistically
significant for REH (p,0.01) and RS4;11 (p,0.03).
doi:10.1371/journal.pone.0015262.g003
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frequency of ALDH
+ cells in each cell line compared to control
vehicle treated cells, suggesting that the Hh pathway activity
maintains this self-renewing population of cells (Figure 3D,
p,0.01 for REH, p,0.03 for RS4;11). We also examined the
effects of Hh pathway modulation on in vitro clonogenic growth
and treated REH and RS4;11 cells with SHh-NP, 5E1,
cyclopamine or IPI-926. Following 72 hours of treatment, SHh-
NP significantly increased colony formation both during primary
and secondary plating (Figure 4A, p,0.001). In contrast, Hh
pathway inhibition by 5E1 or either SMO inhibitor had no or only
minor effects on colony formation after initial plating compared to
vehicle treated control cells. However, upon serial replating
(without further exposure to drug), secondary colony formation
was significantly inhibited by each of these agents (Figure 4B,
p,0.02 for REH and p,0.001 for RS4;11). Moreover, the effects
of Hh pathway inhibition were long-lasting as decreased colony
formation was maintained for at least 28 days following initial
treatment.
Hh inhibition with IPI-926 limits B-ALL self-renewal in vivo
Primary colony-formation assays in methylcellulose demon-
strate effects on tumorigenic potential of these leukemia cells. Our
finding that the effects of Hh inhibition on leukemic growth
persisted through serial replating without further exposure to drug
suggests that Hh signaling is involved in the regulation of long-
term self-renewal as well. To further investigate the effects of Hh
inhibition on self renewal and the relevance of the Hh signaling
pathway as a therapeutic target in human B-ALL, we examined
the activity of IPI-926 against REH cells in vivo. NOD/Scid mice
were injected with REH cells then treated with IPI-926 or vehicle
control for 21 days. There was no significant difference in median
survival between the untreated and IPI-926 treated groups and all
mice demonstrated engraftment of human leukemia by flow
cytometry (Figure 5). To examine effects of short-term Hh
inhibition on long-term self-renewal, we isolated human CD19
+
cells from the bone marrow of mice from each treatment group
and injected equivalent numbers of tumor cells into secondary
recipients. Following 60 days, all mice receiving tumor cells from
vehicle treated animals engrafted with leukemia. In contrast,
leukemic engraftment was detected in only 1 of 5 recipient mice
receiving bone marrow from IPI-926 treated donors (Table 2)
although none of the secondary recipients received further
treatment. These results demonstrate a persistent effect of Hh
inhibition on the long-term self-renewing cells in B-ALL.
Hh signaling affects B-cell ALL self-renewal in a cell
intrinsic manner
Recent data in mouse models of pancreatic and colon cancer
have suggested that the Hh signaling pathway mediates interac-
tions between tumor cells and the non-cancerous stromal cells in
the microenvironment [29]. Here, tumor cells secrete Hh ligand
Figure 4. Hh pathway regulates self-renewal in precursor B-ALL. Clonogenic recovery of REH and RS4;11 cells following treatment with Hh
pathway agonist and inhibitors. B-ALL cells were treated with Hh pathway modulators for 72 hours, washed free of drug and plated in quadruplicate
in methylcellulose. At 10–14 days, colonies were counted (represented as initial plating). A representative plate was then washed and cells
resuspended and replated. After an additional 10–14 days, colonies were counted (represented as secondary replating). Clonogenic recovery of
untreated cells was normalized to 100% and plating results from all treatment groups are expressed as % control 6 SEM. (A)Colony-formation of REH
and RS4;11 cells following treatment with the Hh pathway ligand SHhNP. Increased colony-formation was statistically significant in both cell lines at
initial and secondary replating despite no further addition of drug (p,0.001 for all groups). (B) Colony-formation of REH and RS4;11 cells following
treatment with Hh pathway inhibitors 5E1 (10 mg/ml), cyclopamine (5 mM), IPI-926 (1 mM). Inhibition of clonogenic growth at secondary replating for
both REH and RS4;11 cells was statistically significant (p,0.02) with Hh pathway inhibition with 5E1, cyclopamine and IPI-926.
doi:10.1371/journal.pone.0015262.g004
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in turn, are thought to elaborate factors promoting tumor cell
growth and survival. Since our initial in vivo studies were unable to
distinguish anti-tumor effects arising from pathway inhibition
within tumor or stromal cells, we treated REH cells in vitro for two
weeks with IPI-926, washed cells to remove drug, and then
evaluated tumor growth in NOD/Scid mice. Although in vitro
treatment did not inhibit B-ALL engraftment, mice injected with
cells pre-treated with IPI-926 had a significantly prolonged overall
survival (50 versus 70 days, p,0.001, Figure 6). Therefore,
inhibition of the Hh pathway within B-ALL cells may directly
impact tumor growth and disease progression.
Discussion
Children and adults with newly diagnosed B-ALL respond
equally well to induction chemotherapy with over 90% of patients
achieving a complete remission. However, long-term outcomes
markedly differ as the majority of children are cured whereas most
adults relapse and die of progressive disease. Initial responses
indicate that induction chemotherapy is effective at eliminating the
majority of tumor cells, but subsequent relapse suggest that
alternative means of inhibiting persistent leukemic cells capable of
long-term self-renewal are needed.
In several human cancers, long-term growth potential appears
to be restricted to distinct populations of CSC that share functional
attributes with their normal counterparts, including self-renewal
and the ability to give rise to differentiated progeny that form the
tumor bulk. The identification of CSC in most human tumors has
relied on distinct patterns of surface antigen expression. In B-ALL,
the CSC surface phenotype is not clear since several unique
markers have been used to isolate clonogenic cells.
16–21 It is
possible that specific antigen expression by CSC may vary among
individual cases of B-ALL as a function of distinct genetic
abnormalities [30-32] or stage of disease [33]. Rather than surface
antigen expression, we examined intracellular ALDH activity since
this approach can enrich for normal stem cells in several adult
tissues [24,25,34]. Similar to several other malignancies, including
MM, classical Hodgkin lymphoma, and breast and pancreatic
carcinomas [6,10,27,35,36], we found that relative ALDH activity
could enrich for B-ALL cells with increased growth potential.
Moreover, ALDH
+ cells displayed increased clonogenic expansion
during serial passage compared to ALDH
neg cells suggesting that
they had increased self-renewal potential.
Similar to normal stem cells, CSC self-renewal is required for
long-term maintenance of the malignant clone. Therapeutic
approaches that target self-renewal may improve long-term
outcomes, but few approaches have been developed that target this
property. Serial transplantation is widely accepted as an assay
measuringlong-termself-renewalinnormalhematopoieticstemcells
and other malignancies. We used a complementary in vitro assay with
serial replating and colony-formation, as well as serial in vivo
transplantationinorderto assessthe effects ofHhinhibition on long-
term self-renewal. We found that the Hh pathway inhibitors 5E1,
cyclopamine or the novel semi-synthetic cyclopamine derivative IPI-
926 significantly reduced B-ALL cell self-renewal in vitro as well as
during serial transplantation in vivo.T h i sl o s so fs e r i a lt r a n s p l a n t a t i o n
Figure 5. Engraftment of human leukemia cells in NOD/Scid mice. Representative flow cytometry results of mouse bone marrow
demonstrating engraftment of human leukemia. Mice were injected with REH cells and then treated with either vehicle control or IPI-926 for 21 days.
Mouse bone marrow was harvested after development of symptoms and analyzed by flow cytometry for the presence of human leukemia cells. All
mice in both treatment groups had engraftment of human leukemia cells that were mouse CD45 negative, human CD45 positive and human CD19
positive.
doi:10.1371/journal.pone.0015262.g005
Table 2. Rates of secondary leukemia engraftment following
in vivo treatment with IPI-926.
Engraftment Secondary engraftment
IPI-926 5/5 1/5
Vehicle 5/5 5/5
An initial cohort of mice was injected with REH cells and treated with either IPI-
926 or vehicle control. All mice engrafted with leukemia. Following secondary
transplantation of harvested bone marrow cells, 1 in 5 recipient mice of the
bone marrow from IPI-926 treated mice engrafted with leukemia versus 5 in 5
recipient mice of vehicle-control (p,0.04).
doi:10.1371/journal.pone.0015262.t002
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transplantation experiments with normal hematopoietic stemcells.It
is notable that such long-lasting effects of Hh inhibition were seen
following only short exposure to drug (either 72 hours in the colony-
formation assays or 21 days of treatment in the primary recipient
mice only). Based on our in vitro clonogenic data, we believe that this
loss of serial colony-formation and transplantation ability is due to
the effects of Hh inhibition on the self-renewal properties of B-ALL
CSC. However, it is possible that the inhibition of engraftment
during secondary transplantation is mediated by the effects of Hh
inhibition on the quiescence of CSC, their ability to interact with
potential stem cell niches, proper homing during transplanta-
tion, or the induction of terminal differentiation. Although cell
reprogramming may be an interesting consideration, there is no
current data to suggest that this that this process happens in any
disease. Similarlimitation of self-renewalfollowing Hhinhibition has
been reported for MM and CML [6,18,19], suggesting that the Hh
signaling pathway may regulate self-renewing cells across several
malignancies and represent a novel approach to therapeutically
target long-term self-renewal.
Several models of Hh pathway activation in cancer have been
described [37,38]. Distinct tumors, such as BCC and medulloblas-
toma, may harbor mutations in PTCH1 or SMO that leads to
constitutive pathway activation in the absence of HH ligand
[39,40]. Autocrine signaling in which tumor cells both secrete and
respond to ligand has also been described in a wide variety of
human solid tumors [11,14–16,41–43]. In addition, recent data
have suggested that paracrine Hh signaling may mediate interac-
tions between tumor cells and non-transformed stromal cells
through multiple mechanisms [5,26,41,42]. In NHL and MM,
stromal cells have been found to secrete HH ligand that promotes
the survival of malignant plasma cells [8]. In pancreatic and colon
carcinomas, tumor cells secrete ligand and stimulate Hh pathway
activity in stromal cells to promote tumor growth [29,44,45]. This
second paracrine model suggests that Hh signaling primarily occurs
in normal, rather than tumor cells, but data in CML, colon cancer
and our findings in B-ALL suggest that Hh signaling and its
regulation of self-renewal is cell intrinsic [18,19]. Both REH and
RS4;11 cells were responsive to ligand stimulation as measured by
increased GLI1 expression as well as increased clonogenic growth.
In these in vitro models, no stromal cells were used, and the effects of
Hh activation by SHh and inhibition by 5E1, cyclopamine or IPI-
926 were mediated through a cell intrinsic mechanism. Moreover,
we found that in vitro treatment of REH cells with IPI-926 prior to
injection into mice and in the absence of stromal cells significantly
prolonged survival. The treatment of mice with IPI-926 following
theinjectionofREH cellsalso hada profoundeffect onB-ALLcells,
but primarily on their ability to undergo serial transplantation.
Since B-ALL cells are heavily dependent on bone marrow stromal
cells for their survival and growth, it is likely that the Hh signaling
may occur through multiple modes in B-ALL.
In several human cancers, such as MM, the Hh signaling
pathway may be active in only a portion of cases [6,23]. In
contrast, we found the expression of HH pathway components is a
feature of both good risk (i.e., t(12;22) and poor risk (i.e., MLL-
rearranged or Ph
+) subtypes of B-ALL. Therefore, Hh signaling
may represent a common therapeutic target in this disease,
perhaps due to a role in early lymphoid development [7,46]. Since
our data suggest that the Hh pathway specifically targets the self-
renewal of B-ALL cells, the optimal use of novel pathway
inhibitors currently entering clinical testing may be as post-
remission therapy following induction [47].
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Figure 6. Prolonged overall survival of recipient mice of pre-treated IPI-926 REH cells. NOD-Scid mice were injected by tail vein with REH
cells that had been pre-treated with either IPI-926 or vehicle in vitro prior to injection. Mice were followed for progression of symptoms and overall
survival, and recipient mice of pre-treated cells had statistically significantly longer overall survival (70 days versus 50 days, p,0.001).
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